Embracing Femasys Inc.'s ($FEMY) Historic Surge

Written by Fausto Pugliese | Sep 29, 2023 9:16:00 AM

Embracing Femasys Inc.'s ($FEMY) Historic Surge

Femasys Inc. - A Brief Overview

($FEMY) experienced an unprecedented surge, exceeding 600%, driven by the FDA's recent approval of their groundbreaking infertility treatment, FemaSeed. This blog post delves into the remarkable leap, exploring the impact of this innovative treatment on the stock price and the opportunities it has presented to day traders.

The Game-Changing FemaSeed Infertility Treatment:

Femasys Inc. (NASDAQ:FEMY) has made waves with FemaSeed, a groundbreaking infertility treatment designed to deliver sperm directly into a woman’s fallopian tube. This less invasive approach offers an alternative to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), promising a new era in infertility treatments.

With the FDA's approval for FemaSeed, Femasys can now move forward with commercialization, positioning itself in the rapidly growing infertility market. Approximately 10 million women in the U.S. face infertility issues, underscoring the significance of this development.

Kathy Lee-Sepsick, Femasys' founder, president, and CEO, expressed her excitement about the FDA approval, highlighting, “This FDA 510(k) Clearance of FemaSeed demonstrates our successful collaborative efforts with the FDA to bring forward new technology that will address the significant unmet need for less burdensome infertility treatments.”

How This Affects $FEMY Today:

The FDA's approval triggered an incredible surge in FEMY stock trading. Over 9.8 million shares, well above the average daily trading volume of approximately 3.3 million shares, have been exchanged as of this moment. Demonstrating the magnitude of this surge, FEMY stock soared by an astonishing 180.9% during Tuesday morning's trading session, offsetting a challenging year-to-date performance where the stock closed out Monday down by 63.2%.

Final Thoughts

Femasys Inc.'s historic 600%+ surge, fueled by the FDA approval for FemaSeed, has set the day trading community abuzz. The heightened volatility and price movements have laid the foundation for potential profits and exhilarating trading opportunities. However, prudent risk management and a strategic approach are essential for day traders looking to capitalize on this extraordinary market movement.

Wishing you all profitable trades and success in your endeavors.

See you tomorrow in my CyberGroup Live Trading room (Open Monday thru Friday from 7:45am - 4:30pm EST)

If you aren't already a member, you can sign up today at https://ctu.co/trial

Happy Trading,

Fausto Pugliese
Founder & CEO
Cyber Trading University

Share this article:

Fausto Pugliese

Fausto Pugliese is founder and president of Cyber Trading University. Pugliese began his career on Wall Street as a stockbroker and was one of the first independent traders to take advantage of the Direct Access Trading technology boom that started in 1987. He has appeared on Fox News, CNBC, and other financial shows. Fausto was one of the original Day Traders of the early 1990’s and one of the first independent traders to take advantage of the Direct Access Trading technology boom in 1987. He acquired a wealth of knowledge from years of hands on experience, beginning in the trenches, working side by side with some of the most practiced and successful traders in the industry. After spending considerable time mastering the art and discipline of day trading, Fausto chose to start his own company to share some of his highly-sought-after wisdom.

Subscribe to Cyber Trading University on YouTube for Live Trading, Daily Live Streams, Meetings, and Watch List Analysis by Fausto and Josh, or follow us on Facebook, or Twitter

Sign Up for Fausto's Next FREE Workshop on September 29, 2023

Watch Fausto's Latest Free Workshop Now

View full post